What's New in Health and Life Sciences
News from the European Comission
EUROPA - Research and Innovation: Health & Life Sciences
DG Research & Innovation invites you to take part in the two interactive sessions organised at the European Health Forum Gastein.
- • Workshop on 4 October: "Personalised healthcare: How rare diseases pave the way", will focus on rare diseases research and care in Europe, the use of "omics" & Real-World Data, health data infrastructures and health data policy.
• Session on 5 October: "Environment & Health: Building the evidence base for policy", will highlight the important role research plays in establishing and maintaining a strong evidence base for policy-making in the steadily evolving area of environment and health.
The big data revolution promises transformational potential for healthcare through data-driven improvements in research & development, care delivery, and policy-making.
As health systems around the world routinely collect a wealth of data every day, we are facing the question: how can we use big data to improve patient’s lives?
In a public lecture, Dr Jem Rashbass (National Director Disease Registration and Cancer Analysis at Public Health England) will outline how health systems can turn big data into information.
A high-profile panel will comment on how this information ca be put to use, implications of big data for healthcare system transformation, and patients’ perspectives on the collection and use of highly personal data.
The European Research Infrastructure for Translational Medicine (EATRIS) organises its third bi-annual conference, “Translational Medicine 2017” on September 24-26 2017 at the Corinthia Hotel in Prague.
This event, open to a wide range of stakeholders from academic researchers, funders to industry players and regulators, will bring together international experts to discuss the latest advancements in translational medicine.
The theme of this third edition, “Enhancing Predictivity in Medicines Development” will focus on bringing together the latest technologies to increase success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.